Invention Application
- Patent Title: LILRB2-SPECIFIC MONOCLONAL ANTIBODIES AND METHODS OF THEIR USE
-
Application No.: US18691249Application Date: 2022-09-13
-
Publication No.: US20240392001A1Publication Date: 2024-11-28
- Inventor: Zhiqiang AN , Ningyan ZHANG , Peng ZHAO
- Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
- Applicant Address: US TX Austin
- Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
- Current Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
- Current Assignee Address: US TX Austin
- International Application: PCT/US2022/076383 WO 20220913
- Main IPC: C07K16/28
- IPC: C07K16/28
Abstract:
Isolated or recombinant anti-LILRB2 monoclonal antibodies are provided. In some embodiments, the antibodies herein can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as Alzheimer's Disease. In further aspects, the LILRB2-binding antibodies can affect cellular signaling mediated through at least the oA and PS-mediated TREM2 and LILRB2 co-ligation signaling pathway and can be used to modulate microglia function.
Information query
